ARNA - アリ―ナ・ファ―マシュ―ティカルズ (Arena Pharmaceuticals Inc.) アリ―ナ・ファ―マシュ―ティカルズ

 ARNAのチャート


 ARNAの企業情報

symbol ARNA
会社名 Arena Pharmaceuticals Inc (アリ―ナ・ファ―マシュ―ティカルズ)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 アリーナ・ファーマシューティカルズ(Arena Pharmaceuticals Inc.)はバイオ医薬品会社である。同社は治療領域にわたって小分子薬物の開発に従事する。同社は、潰瘍性大腸炎の第II相評価におけるエトラサモード(APD334)、クローン病に関連する疼痛の治療のための第II相評価に入るAPD371、及び肺動脈性高血圧(PAH)の第II相評価におけるralinepag(APD811)の3つの主要治験臨床プログラムを有する。同社の医薬品であるLorcaserinは、体重管理の指標として米国と韓国で販売承認を受ける。同社の臨床開発における候補者には、自己免疫疾患のためのAPD334、血管疾患のためのralinepag及び疼痛のためのAPD371が含まれる。同社の協力プログラムには、認知症関連精神病のネロタンセリン、血栓性疾患のテマノグレル、中枢神経系(CNS)適応症の非公開孤児GPCRが含まれる。   アリ―ナ・ファ―マシュ―ティカルズは、米国のバイオ医薬品会社。医薬品医療ニ―ズに対応するため、Gタンパク質共役型受容体を標的とする薬剤を開発、商品化する。同社が開発した肥満症治療剤「BELVIQ」は、米国食品医薬品局(FDA)に唯一承認された薬剤である。そのほか、肺動脈高血圧症の治療のためのAPD811など、研究開発中の薬剤候補がある。   Arena Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel drugs that target G protien-coupled receptors. It offers drugs for treatment in the field of cardiovascular, central nervous system, inflammatory, and metabolic diseases. The company was founded by Dominic P. Behan and Jack Lief on April 14, 1997 and is headquartered in San Diego, CA.
本社所在地 6154 Nancy Ridge Drive San Diego CA 92121 USA
代表者氏名 Tina Susan Nova ティナ・スーザン・ノヴァ
代表者役職名 Independent Chairman of the Board
電話番号 +1 858-453-7200
設立年月日 35521
市場名 NASDAQ National Market System
ipoyear 2000年
従業員数 106人
url www.arenapharm.com
nasdaq_url https://www.nasdaq.com/symbol/arna
adr_tso
EBITDA EBITDA(百万ドル) -98.92900
終値(lastsale) 39.7
時価総額(marketcap) 1959123103.3
時価総額 時価総額(百万ドル) 1962.084
売上高 売上高(百万ドル) 13.97000
企業価値(EV) 企業価値(EV)(百万ドル) 1429.45
当期純利益 当期純利益(百万ドル) -112.12500
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Arena Pharmaceuticals Inc. revenues increased 62% to $5.7M. Net loss before extraordinary items increased 38% to $63M. Revenues reflect Royalty revenue increase from $0K to $1.6M Collaboration and other revenue increase of 17% to $4.2M. Higher net loss reflects Research and development increase of 39% to $44.7M (expense) General and administrative - increase of 41% to $16.6M (expense).

 ARNAのテクニカル分析


 ARNAのニュース

   The Daily Biotech Pulse: Moderna Inks 2 R&D Deals, BioNTech To Buy Manufacturing Facility, Dyne Therapeutics IPO  2020/09/17 11:59:47 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 16) Arena Pharmaceuticals, Inc. (NASDAQ: ARNA ) (the first subject has been dosed in a Phase 3 trial evaluating etrasimod for the potential treatment of moderately to severely active ulcerative colitis) Beigene Ltd (NASDAQ: BGNE ) BioLife Solutions Inc (NASDAQ: BLFS ) Checkpoint Therapeutics Inc (NASDAQ: CKPT ) Denali Therapeutics Inc (NASDAQ: DNLI ) Dr.Reddy's Laboratories Ltd (NYSE: RDY ) (announced a deal with Russia for 100 million doses of Sputnik-V vaccine against the coronavirus) Fortress Biotech (NASDAQ: FBIO ) Guardant Health Inc (NASDAQ: GH ) Immunovant Inc (NASDAQ: IMVT ) Insmed Incorporated (NASDAQ: INSM ) InVitae Corp (NYSE: NVTA ) Marinus Pharmaceuticals Inc (NASDAQ: MRNS ) Mersana Therapeutics Inc (NASDAQ: MRSN ) Mirati Therapeutics Inc (NASDAQ: MRTX ) Myokardia Inc (NASDAQ: MYOK ) Nevro Corp (NYSE: NVRO ) Novocure Ltd (NASDAQ: NVCR ) Pacific Biosciences of California Inc (NASDAQ: PACB ) Protagonist Therapeutics Inc (NASDAQ: PTGX ) RedHill Biopharma Ltd (NASDAQ: RDHL ) Revance Therapeutics Inc (NASDAQ: RVNC ) SI-Bone Inc (NASDAQ: SIBN ) Silk Road Medical Inc (NASDAQ: SILK ) Turning Point Therapeutics Inc (NASDAQ: TPTX ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows Sept. 16) PainReform Ltd (NASDAQ: PRFX ) Pandion Therapeutics Inc (NASDAQ: PAND ) SILENCE THERAPE/S ADR (NASDAQ: SLN ) Stocks In Focus Moderna Announces 2 R&D Collaborations For Up To $880M Moderna Inc (NASDAQ: MRNA ) and Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX ) announced a three-year strategic research collaboration and licensing agreement aimed at the discovery and development of lipid nanoparticles and mRNAs for the delivery of gene-editing therapies for cystic fibrosis.
   Arena Pharmaceuticals, Inc. (ARNA) CEO Amit Munshi Presents at Cantor 2020 Global Virtual Healthcare Conference (Transcript)  2020/09/16 20:19:10 Seeking Alpha
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) Cantor 2020 Global Virtual Healthcare Conference September 16, 2020 02:00 PM ET Company Participants Amit Munshi - Director, President & Chief Executive Officer Conference Call Participants Alethia Young - Cantor Fitzgerald Presentation Alethia Young Everybody, it's Alethia Young here.
   Arena Pharmaceuticals to Release Second Quarter 2020 Financial Results and Provide Corporate Update on August 5  2020/07/29 20:01:00 PR Newswire
SAN DIEGO, July 29, 2020 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) will release its second quarter 2020 financial results and provide a corporate update on Wednesday, August 5, 2020, after the close of the U.S. financial markets. The Company will host a question and…
   Arena Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)  2020/06/18 20:01:00 PR Newswire
SAN DIEGO, June 18, 2020 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that on June 15, 2020, the Compensation Committee of its Board of Directors granted inducement stock options to purchase an aggregate of 80,250 shares of its common stock to 12 new…
   Arena Pharmaceuticals Appoints Biotech Executive Katharine Knobil, M.D., to Board of Directors  2020/06/15 12:30:00 PR Newswire
SAN DIEGO, June 15, 2020 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced the appointment of Dr. Katharine Knobil to the Company's Board of Directors. Dr. Knobil brings more than 20 years of leadership and expertise across a range of areas including global…
   Arena Pharmaceuticals (ARNA) Q1 Loss Narrower Than Expected  2020/05/08 14:39:00 Zacks Investment Research
Arena Pharmaceuticals (ARNA) beats bottom-line estimates in the first quarter of 2020. Clinical progress remains on track amid COVID-19 pandemic.
   Arena Pharmaceuticals to Present at the Bank of America Securities Healthcare Conference on May 13  2020/05/06 12:30:00 PR Newswire
SAN DIEGO, May 6, 2020 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that Preston Klassen, MD, MHS, the Company's Executive Vice President, Head of Research & Development, is scheduled to participate in a virtual fireside chat at the Bank of America Securities…
   Arena Pharmaceuticals to Release First Quarter 2020 Financial Results and Provide Corporate Update on May 7  2020/04/30 12:30:00 PR Newswire
SAN DIEGO, April 30, 2020 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) will release its first quarter 2020 financial results and provide a corporate update on Thursday, May 7, 2020, after the close of the U.S. financial markets. The Company will host a question and answer…
   Arena Pharmaceuticals Announces Positive Topline Data for New Development Program - Etrasimod Controlled-Release (CR)  2020/04/01 20:01:00 PR Newswire
/PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced positive topline data from a Phase 1 clinical study evaluating controlled-release…
   The Daily Biotech Pulse: Roche Obtains FDA Emergency Use Authorization For COVID-19 Test, Chembio Appoints New CEO, Inovio Slumps On Earnings  2020/03/13 11:52:53 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs March 12.) Masimo Corporation (NASDAQ: MASI ) Down In The Dumps (Biotech stocks that hit 52-week lows March 12.) Abbott Laboratories (NYSE: ABT ) ABIOMED, Inc. (NASDAQ: ABMD ) Acasti Pharma Inc (NASDAQ: ACST ) Accelerate Diagnostics Inc (NASDAQ: AXDX ) AcelRx Pharmaceuticals Inc (NASDAQ: ACRX ) Achieve Life Sciences Inc (NASDAQ: ACHV ) Acorda Therapeutics Inc (NASDAQ: ACOR ) Adamas Pharmaceuticals Inc (NASDAQ: ADMS ) Adamis Pharmaceuticals Corp (NASDAQ: ADM ) Adaptive Biotechnologies Corp (NASDAQ: ADPT ) ADDEX THERAPEUT/ADR (NASDAQ: ADXN ) ADMA Biologics Inc (NASDAQ: ADMA ) Aeglea Bio Therapeutics Inc (NASDAQ: AGLE ) Aerie Pharmaceuticals Inc (NASDAQ: AERI ) AEterna Zentaris Inc. (NASDAQ: AEZS ) Affimed NV (NASDAQ: AFMD ) Aileron Therapeutics Inc (NASDAQ: ALRN ) Aimmune Therapeutics Inc (NASDAQ: AIMT ) Akari Therapeutics PLC (NASDAQ: AKTX ) Akcea Therapeutics Inc (NASDAQ: AKCA ) Akero Therapeutics Inc (NASDAQ: AKRO ) Akers Biosciences Inc (NASDAQ: AKER ) Akorn, Inc.
   FDA Grants Fast Track Designation to Arena Pharmaceuticals' APD418 for Development in Decompensated Heart Failure Patients  2020/01/16 14:00:00 PR Newswire
SAN DIEGO, Jan. 16, 2020 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that the U.S. Food and Drug Administration (FDA) granted Fast Track designation for APD418, a β3-adrenergic receptor (AdrR) antagonist and cardiac myotrope, in development for the treatment…
   IN BRIEF: Arena Pharmaceuticals swipes top lawyer from DBV Technologies  2020/01/14 23:50:06 Reuters
Arena Pharmaceuticals Inc has tapped Joan Schmidt, a lawyer with decades of in-house experience at biopharmaceutical companies, to replace its general counsel, who is retiring in March.
   Arena Pharmaceuticals to Present at the 38th Annual J.P. Morgan Healthcare Conference on January 16  2020/01/08 13:30:00 PR Newswire
SAN DIEGO, Jan. 8, 2020 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that Amit D. Munshi, the Company's President and Chief Executive Officer, will present a corporate update at the 38th Annual J.P. Morgan Healthcare Conference on Thursday, January 16, at…
   Arena Pharmaceuticals verkündet strategischen Wachstumsplan für die nahe und ferne Zukunft mit acht Phase-2- und Phase-3-Datenauslesungen in 2020-21 und einem neuen Prüfpräparat (IND) pro Jahr für die kommenden 5 Jahre  2020/01/07 19:58:00 PR Newswire
- Beginn des Phase-2/3-Programms zu Etrasimod bei Morbus Crohn (CD) - Zwei zusätzliche Phase-2-Entwicklungsprogramme zu Etrasimod bei eosinophiler Ösophagitis (EoE) und Alopecia areata (AA) - Dosierung des ersten Prüfungsteilnehmers in Phase-1-Prüfung zu APD418 bei dekompensierter…
   El plan estratégico de Arena Pharmaceuticals incluye lecturas de datos de fases II y III en 2020-21 y un nuevo IND anual  2020/01/07 19:41:00 PR Newswire
- Arena Pharmaceuticals subraya su plan estratégico con el que generará crecimiento a corto y largo plazo con ocho lecturas de datos de fases II y III en 2020-21 y un nuevo IND al año durante los próximos 5 años - Inicio del programa de fase II/III con etrasimod en la enfermedad de Crohn…

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 アリ―ナ・ファ―マシュ―ティカルズ ARNA Arena Pharmaceuticals Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)